EXELIXIS INC. DL-,01EXELIXIS INC. DL-,01EXELIXIS INC. DL-,01

EXELIXIS INC. DL-,01

No trades
See on Supercharts
Next report date
Report period
Q2 2024
EPS estimate
0.29EUR
Revenue estimate
‪443.41 M‬EUR
Market capitalization
‪6.48 B‬EUR
‪188.24 M‬EUR
‪1.66 B‬EUR
‪286.65 M‬
Beta (1Y)
0.50

About Exelixis, Inc.

CEO
Michael M. Morrissey
Headquarters
Alameda
Employees (FY)
‪1.31 K‬
Founded
1994
FIGI
BBG000BL3426
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where EX9 is featured.

Frequently Asked Questions

Depending on the exchange, the stock ticker may vary. For instance, on MUN exchange EXELIXIS INC. DL-,01 stocks are traded under the ticker EX9.
EXELIXIS INC. DL-,01 is going to release the next earnings report on Jul 31, 2024. Keep track of upcoming events with our Earnings Calendar.
EX9 earnings for the last quarter are 0.24 EUR per share, whereas the estimation was 0.21 EUR resulting in a 17.56% surprise. The estimated earnings for the next quarter are 0.21 EUR per share. See more details about EXELIXIS INC. DL-,01 earnings.
EXELIXIS INC. DL-,01 revenue for the last quarter amounts to ‪434.57 M‬ EUR despite the estimated figure of ‪435.18 M‬ EUR. In the next quarter revenue is expected to reach ‪427.29 M‬ EUR.
Yes, you can track EXELIXIS INC. DL-,01 financials in yearly and quarterly reports right on TradingView.
EX9 net income for the last quarter is ‪77.48 M‬ EUR, while the quarter before that showed ‪984.78 K‬ EUR of net income which accounts for ‪7.77 K‬% change. Track more EXELIXIS INC. DL-,01 financial stats to get the full picture.
No, EX9 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, EX9 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade EXELIXIS INC. DL-,01 stock right from TradingView charts — choose your broker and connect to your account.
EX9 reached its all-time high on Jul 24, 2000 with the price of 53.500 EUR, and its all-time low was 1.070 EUR and was reached on Dec 17, 2014.
See other stocks reaching their highest and lowest prices.
As of May 1, 2024, the company has ‪1.31 K‬ employees. See our rating of the largest employees — is EXELIXIS INC. DL-,01 on this list?
We've gathered analysts' opinions on EXELIXIS INC. DL-,01 future price: according to them, EX9 price has a max estimate of 30.00 EUR and a min estimate of 15.94 EUR. Read a more detailed EXELIXIS INC. DL-,01 forecast: see what analysts think of EXELIXIS INC. DL-,01 and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. EXELIXIS INC. DL-,01 EBITDA is ‪190.79 M‬ EUR, and current EBITDA margin is 10.74%. See more stats in EXELIXIS INC. DL-,01 financial statements.